Insulin pump maker Insulet has acquired Automated Glucose Control LLC's assets related to its automated insulin delivery technology for $25 million.
The companies have had an established partnership since 2016. The Calif.-based company's founders consulted with Insulet during the development of its Omnipod 5 Automated Insulin Delivery system.
"AGC played a critical role in facilitating the...
Mass.-based insulin-pump maker Insulet acquired assets related to Bigfoot Biomedical's pump-based automated insulin delivery (AID) technologies for $25 million.
Insulet and Bigfoot offer two distinct forms of diabetes-management care: Insulet's Omnipod system that delivers insulin via a wearable, tubeless pump dubbed the Pod; and a remote controller called the Personal Diabetes Manager (PDM)....
Mass.-based medical device company Insulet issued a notice of a data breach that may have compromised the protected health information of 29,000 users of its recently recalled Omnipod DASH Insulin Management System.
In November, the FDA posted a notice about a Class I recall of Insulet's Omnipod DASH Insulin Management System Personal Diabetes Manager, following complaints about the battery,...
The FDA posted a notice saying the recall of Insulet's Omnipod DASH Insulin Management System Personal Diabetes Manager is a Class I, the most serious recall indicating the devices could cause serious injuries or death.
The Massachusetts-based company's system consists of two parts: A wearable and tubeless pump that delivers insulin, dubbed the Pod, and a remote controller with a battery pack...
Talkspace reported a growing net loss in the third quarter as the teletherapy company continues to shift to a business-to-business model from a consumer-facing product.
It reported an $18 million net loss compared with $2 million loss in the prior-year period, which it attributes to a lower marketing spend. Talkspace posted revenue of $29 million, an 11% increase from 2021. The company also noted...
Insulin pump-maker Insulet reported net income of $27.8 million during the first quarter this year, months after it received FDA 510(k) clearance for its Omnipod 5 automated insulin delivery system.
The company also posted $295.4 million in revenue during Q1, compared with $252.3 million in the prior year, beating expectations. Insulet is currently building a limited launch of the Omnipod 5 and...
Insulin pump-maker Insulet has scored FDA 510(k) clearance for its Omnipod 5 Automated Insulin Delivery System for people ages 6 and up with Type 1 diabetes. The pump integrates with the Dexcom G6 continuous glucose monitor to automatically adjust insulin levels depending on blood glucose. It can be worn for up to 72 hours.
Users can control their pump and share data from an app if they have a...
Insulin pump maker Insulin announced partnerships yesterday with two of the leading continuous glucose monitor companies, Abbott and Dexcom. Both involve the Insulet’s Omnipod Horizon Automated Insulin Delivery System which uses a tubeless, wearable “Pod” to deliver insulin for 72 hours at a time.
Abbott and Insulet have partnered to offer a new integrated digital health platform that will...
Editor's note: The headline and body of this article has been edited to clarify that Samsung's integration with the Omnipod Dash have not yet been implemented.
Samsung Galaxy smartphones will be serving as the controlling device for Billerica, Massachusetts-based Insulet Corporation’s tubeless insulin pump devices, the two companies announced today.
Insulet’s recently FDA-cleared Omnipod Dash...
Billerica, Massachusetts-based Insulet Corporation, maker of the OmniPod Insulin pump, has just announced that it received the FDA clearance to commercialize its latest product the Omnipod Dash Insulin Management System.
“Omnipod Dash was inspired by Podders and embodies what users on multiple daily injections have been asking for in a diabetes management system,” Patrick Sullivan, chairman and...
